-
-
-
-
-
-
-
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
-
-
-
-
-
-
-
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
-
-
-
-
-
-
-
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
-
-
-
-
-
-
-
RenovoRx (RNXT) Reports Initial Revenues from RenovoCath Commercialization, Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
-
-
-
-
-
-
-
RenovoRx (RNXT) Appoints Michel Ducreux to its Board
-
-
-
-
-
-
-
RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer
-
-
-
-
-
-
-
RenovoRx (RNXT) Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic
-
1,231,056 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


